Cargando…
Double Arylation of the Indole Side Chain of Tri- and Tetrapodal Tryptophan Derivatives Renders Highly Potent HIV-1 and EV-A71 Entry Inhibitors†
[Image: see text] We have recently described a new generation of potent human immunodeficiency virus (HIV) and EV-A71 entry inhibitors. The prototypes contain three or four tryptophan (Trp) residues bearing an isophthalic acid moiety at the C2 position of each side-chain indole ring. This work is no...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2021
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8389807/ https://www.ncbi.nlm.nih.gov/pubmed/34229438 http://dx.doi.org/10.1021/acs.jmedchem.1c00315 |
_version_ | 1783742944026558464 |
---|---|
author | Martí-Marí, Olaia Martínez-Gualda, Belén de la Puente-Secades, Sofía Mills, Alberto Quesada, Ernesto Abdelnabi, Rana Sun, Liang Boonen, Arnaud Noppen, Sam Neyts, Johan Schols, Dominique Camarasa, María-José Gago, Federico San-Félix, Ana |
author_facet | Martí-Marí, Olaia Martínez-Gualda, Belén de la Puente-Secades, Sofía Mills, Alberto Quesada, Ernesto Abdelnabi, Rana Sun, Liang Boonen, Arnaud Noppen, Sam Neyts, Johan Schols, Dominique Camarasa, María-José Gago, Federico San-Félix, Ana |
author_sort | Martí-Marí, Olaia |
collection | PubMed |
description | [Image: see text] We have recently described a new generation of potent human immunodeficiency virus (HIV) and EV-A71 entry inhibitors. The prototypes contain three or four tryptophan (Trp) residues bearing an isophthalic acid moiety at the C2 position of each side-chain indole ring. This work is now extended by both shifting the position of the isophthalic acid to C7 and synthesizing doubly arylated C2/C7 derivatives. The most potent derivative (50% effective concentration (EC(50)) HIV-1, 6 nM; EC(50) EV-A71, 40 nM), 33 (AL-518), is a C2/C7 doubly arylated tetrapodal compound. Its superior anti-HIV potency with respect to the previous C2-arylated prototype is in consonance with its higher affinity for the viral gp120. 33 (AL-518) showed comparable antiviral activities against X4 and R5 HIV-1 strains and seems to interact with the tip and base of the gp120 V3 loop. Taken together, these findings support the interest in 33 (AL-518) as a useful new prototype for anti-HIV/EV71 drug development. |
format | Online Article Text |
id | pubmed-8389807 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Chemical
Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-83898072021-08-31 Double Arylation of the Indole Side Chain of Tri- and Tetrapodal Tryptophan Derivatives Renders Highly Potent HIV-1 and EV-A71 Entry Inhibitors† Martí-Marí, Olaia Martínez-Gualda, Belén de la Puente-Secades, Sofía Mills, Alberto Quesada, Ernesto Abdelnabi, Rana Sun, Liang Boonen, Arnaud Noppen, Sam Neyts, Johan Schols, Dominique Camarasa, María-José Gago, Federico San-Félix, Ana J Med Chem [Image: see text] We have recently described a new generation of potent human immunodeficiency virus (HIV) and EV-A71 entry inhibitors. The prototypes contain three or four tryptophan (Trp) residues bearing an isophthalic acid moiety at the C2 position of each side-chain indole ring. This work is now extended by both shifting the position of the isophthalic acid to C7 and synthesizing doubly arylated C2/C7 derivatives. The most potent derivative (50% effective concentration (EC(50)) HIV-1, 6 nM; EC(50) EV-A71, 40 nM), 33 (AL-518), is a C2/C7 doubly arylated tetrapodal compound. Its superior anti-HIV potency with respect to the previous C2-arylated prototype is in consonance with its higher affinity for the viral gp120. 33 (AL-518) showed comparable antiviral activities against X4 and R5 HIV-1 strains and seems to interact with the tip and base of the gp120 V3 loop. Taken together, these findings support the interest in 33 (AL-518) as a useful new prototype for anti-HIV/EV71 drug development. American Chemical Society 2021-07-07 2021-07-22 /pmc/articles/PMC8389807/ /pubmed/34229438 http://dx.doi.org/10.1021/acs.jmedchem.1c00315 Text en © 2021 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by/4.0/Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Martí-Marí, Olaia Martínez-Gualda, Belén de la Puente-Secades, Sofía Mills, Alberto Quesada, Ernesto Abdelnabi, Rana Sun, Liang Boonen, Arnaud Noppen, Sam Neyts, Johan Schols, Dominique Camarasa, María-José Gago, Federico San-Félix, Ana Double Arylation of the Indole Side Chain of Tri- and Tetrapodal Tryptophan Derivatives Renders Highly Potent HIV-1 and EV-A71 Entry Inhibitors† |
title | Double Arylation
of the Indole Side Chain of Tri-
and Tetrapodal Tryptophan Derivatives Renders Highly Potent HIV-1
and EV-A71 Entry Inhibitors† |
title_full | Double Arylation
of the Indole Side Chain of Tri-
and Tetrapodal Tryptophan Derivatives Renders Highly Potent HIV-1
and EV-A71 Entry Inhibitors† |
title_fullStr | Double Arylation
of the Indole Side Chain of Tri-
and Tetrapodal Tryptophan Derivatives Renders Highly Potent HIV-1
and EV-A71 Entry Inhibitors† |
title_full_unstemmed | Double Arylation
of the Indole Side Chain of Tri-
and Tetrapodal Tryptophan Derivatives Renders Highly Potent HIV-1
and EV-A71 Entry Inhibitors† |
title_short | Double Arylation
of the Indole Side Chain of Tri-
and Tetrapodal Tryptophan Derivatives Renders Highly Potent HIV-1
and EV-A71 Entry Inhibitors† |
title_sort | double arylation
of the indole side chain of tri-
and tetrapodal tryptophan derivatives renders highly potent hiv-1
and ev-a71 entry inhibitors† |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8389807/ https://www.ncbi.nlm.nih.gov/pubmed/34229438 http://dx.doi.org/10.1021/acs.jmedchem.1c00315 |
work_keys_str_mv | AT martimariolaia doublearylationoftheindolesidechainoftriandtetrapodaltryptophanderivativesrendershighlypotenthiv1andeva71entryinhibitors AT martinezgualdabelen doublearylationoftheindolesidechainoftriandtetrapodaltryptophanderivativesrendershighlypotenthiv1andeva71entryinhibitors AT delapuentesecadessofia doublearylationoftheindolesidechainoftriandtetrapodaltryptophanderivativesrendershighlypotenthiv1andeva71entryinhibitors AT millsalberto doublearylationoftheindolesidechainoftriandtetrapodaltryptophanderivativesrendershighlypotenthiv1andeva71entryinhibitors AT quesadaernesto doublearylationoftheindolesidechainoftriandtetrapodaltryptophanderivativesrendershighlypotenthiv1andeva71entryinhibitors AT abdelnabirana doublearylationoftheindolesidechainoftriandtetrapodaltryptophanderivativesrendershighlypotenthiv1andeva71entryinhibitors AT sunliang doublearylationoftheindolesidechainoftriandtetrapodaltryptophanderivativesrendershighlypotenthiv1andeva71entryinhibitors AT boonenarnaud doublearylationoftheindolesidechainoftriandtetrapodaltryptophanderivativesrendershighlypotenthiv1andeva71entryinhibitors AT noppensam doublearylationoftheindolesidechainoftriandtetrapodaltryptophanderivativesrendershighlypotenthiv1andeva71entryinhibitors AT neytsjohan doublearylationoftheindolesidechainoftriandtetrapodaltryptophanderivativesrendershighlypotenthiv1andeva71entryinhibitors AT scholsdominique doublearylationoftheindolesidechainoftriandtetrapodaltryptophanderivativesrendershighlypotenthiv1andeva71entryinhibitors AT camarasamariajose doublearylationoftheindolesidechainoftriandtetrapodaltryptophanderivativesrendershighlypotenthiv1andeva71entryinhibitors AT gagofederico doublearylationoftheindolesidechainoftriandtetrapodaltryptophanderivativesrendershighlypotenthiv1andeva71entryinhibitors AT sanfelixana doublearylationoftheindolesidechainoftriandtetrapodaltryptophanderivativesrendershighlypotenthiv1andeva71entryinhibitors |